Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

Medical groups are optimistic that a recently reintroduced bill to rein in prior authorization has a better chance of passage now than it did last

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it